Busonid® (Budesonide 200 mcg and 400 mcg) to Treat Asthma Not Controlled or Partially Controlled

Inclusion Criteria: * Uncontrolled asthma diagnosis or partially controlled in according to the Guidelines of the Brazilian Society of Pneumology and Phlebology for Asthma Management - 2012; * Capacity of survey participants or legal guardians to understand and consent to the participation of the research participant in this clinical study, expressed by signing the informed consent form; * Ability of children survey participants 18 years understand and nod their participation in this clinical study, manifested by signing the informed assent form; * Baseline forced expiratory volume in one second in screening visit between 55% and 85% of predicted value (before bronchodilator use), including the extremes (ensuring that the lung function test has been performed properly); * Increase of 12% and 200 ml of forced expiratory volume in one second after the reversibility test at screening visit / initiation of treatment. Exclusion Criteria: * Diagnosis of pneumonia, pneumothorax, pneumomediastinum, COPD, pulmonary tuberculosis, deficiency α1anti antitrypsin, lung mycosis (blastomycosis, histoplasmosis), bronchiectasis, pulmonary cystic fibrosis or other significant respiratory disease, according to the investigator; * Pneumothorax history, pulmonary tuberculosis, lung mycosis (blastomycosis, histoplasmosis) and COPD; * Immunosuppressive therapy; * Survey participants with immunosuppression of any kind; * Thoracic surgery history or any prior neoplastic process of the lung; * Significant heart disease; * Four or more systemic corticosteroid courses in the last 12 months; * Participants who have needed hospitalization or care in the emergency room or emergency service (duration\> 12 hours) to airway obstruction control (for exacerbation of asthma), at least once within the last three (03) months; * History of asthma crisis with risk of death; * Ventilatory support needs due to respiratory failure secondary to asthma within the past five (05) years; * Infection of the upper respiratory tract or lower (viral or bacterial) within the last four (04) weeks prior to study entry; * Any finding of clinical observation (clinical evaluation / physical) that is interpreted by the medical researcher as a risk to the research participant in the clinical study; * Known hypersensitivity to drug components used during the study; * Use of forbidden drugs in the clinical study described in Protocol; * Smokers and former smokers; * HIV infection, whether on antiretroviral treatment; * History of abuse of illicit drugs; * Disorders diagnosis of hypothalamic-pituitary-adrenal axis (hypocortisolism or hypercortisolism); * Presence of severe obstruction of lung airflow that may present a risk of death; * Women in reproductive age who do not agree to use hormonal or barrier methods of contraception; except the participants declared that they perform sexual practices or exercise them not to reproductive form; * Female participants in a period of pregnancy or breastfeeding; * Clinical trial protocols of participation in the last twelve (12) months (CNS Resolution 251 of August 7, 1997, Part III, sub-item J), unless the investigator considers that there may be a direct benefit to it; * Family relationship to the second degree or bond with employees or employees of Sponsor and Research Center.